Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618548 | 0.90 | KDM4E (0.36) | KDM4EGRNSORT1 | |
| SCHEMBL10177336 | 0.81 | KDM4E (0.36) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL351489 | 0.80 | CNR2 (0.37) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL10147503 | 0.79 | MAPT (0.37) | MAPK14MAPTLMNAMAPK13MAPK12 | |
| SCHEMBL350334 | 0.78 | CNR2 (0.36) | KDM4EGRNSORT1LMNA | |
| SCHEMBL351891 | 0.78 | CNR2 (0.47) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL351482 | 0.77 | CNR2 (0.32) | KDM4EGRNSORT1 | |
| SCHEMBL10147904 | 0.76 | CNR2 (0.31) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL351110 | 0.74 | CNR2 (0.39) | — | |
| SCHEMBL353288 | 0.74 | CNR2 (0.37) | KDM4EGRNSORT1MAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, TRPV1 | KDM4E 2157/4885GRN 4810/4885SORT1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.